原发器官严重并发症在初诊转移性癌症中的累积发生率与时间特征
该回顾性队列纳入358例初诊转移性前列腺癌、膀胱癌和胰腺癌患者,采用Fine-Gray竞争风险模型估算严重原发器官相关事件(SPORE)的累积发生率。24个月时四组SPORE累积发生率分别为3.3%、27.2%、40.0%和45.5%(p < 0.001),且发生风险与总生存不平行,提示原发肿瘤解剖脆弱性而非转移侵袭性或预后是主要驱动因素。
要点
- 24个月SPORE累积发生率因原发部位和病理类型而异,范围3.3%至45.5%。
- 前列腺癌和膀胱癌以尿路梗阻为主,胰腺癌以胆道梗阻或胆管炎为主。
- 胰腺导管腺癌与神经内分泌肿瘤均显示高局部并发症风险。
核心结论
- SPORE是初诊转移性癌症的重要并发症来源,其风险和时间特征主要由原发肿瘤解剖脆弱性驱动而非转移侵袭性或预后。
- 胰腺导管腺癌和神经内分泌肿瘤尽管生物学不同,均表现出高局部并发症风险。
- 解剖背景可能比预后因素更能识别最可能从预防性局部治疗中获益的患者。
研究设计与样本
- 回顾性队列研究,纳入2010至2023年间治疗的358例初诊转移性前列腺癌、膀胱癌和胰腺癌患者。
- SPORE采用具有临床意义的器官特异性标准定义,排除诊断后30天内的事件。
- 死亡作为竞争事件,采用Fine-Gray方法估算累积发生率函数。
主要发现
- 共纳入104例前列腺癌、59例膀胱癌和195例胰腺癌患者(腺癌178例,神经内分泌肿瘤17例,含头体和体部肿瘤)。
- 24个月SPORE累积发生率分别为3.3%、27.2%、40.0%和45.5%(p < 0.001)。
- 总生存因疾病部位而异,但与SPORE风险不平行。
- 膀胱癌和胰腺腺癌的SPORE发生率在24个月后趋于平台,而前列腺癌和胰腺神经内分泌肿瘤持续增加。
- 胰腺肿瘤中,头部与体部肿瘤24个月SPORE发生率分别为48.5%和32.7%(p = 0.054)。
关键数值与推荐
- SPORE定义采用临床意义明确的器官特异性标准,排除诊断后30天内事件。
- 24个月SPORE累积发生率:前列腺癌3.3%、膀胱癌27.2%、胰腺腺癌40.0%、胰腺神经内分泌肿瘤45.5%(p < 0.001)。
- 胰腺头 vs 体部肿瘤24个月SPORE发生率48.5% vs 32.7%(p = 0.054)。
临床怎么用
- 对初诊转移性前列腺癌和膀胱癌患者应关注尿路梗阻风险,胰腺癌患者应关注胆道梗阻或胆管炎风险。
- SPORE风险与总生存不平行,预防性局部治疗试验设计可依据原发肿瘤解剖部位而非仅预后因素选择人群。
- 胰腺癌患者无论腺癌或神经内分泌肿瘤均需评估局部并发症风险。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- 样本仅限前列腺癌、膀胱癌和胰腺癌三种原发部位,结论外推需谨慎。
- SPORE定义基于器官特异性标准,不同研究间可比性可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with de novo metastatic cancer develop local organ-related complications leading to hospitalizations, procedures, and reduced quality of life. Prophylactic local therapy (e.g., radiotherapy) has been proposed to reduce morbidity, but the incidence and timing of severe primary organ-related events (SPOREs) remain poorly defined. We quantified the cumulative incidence and spectrum of SPOREs to inform trials of prophylactic local therapy. METHODS: We conducted a retrospective cohort study of 358 patients with de novo metastatic prostate, bladder, and pancreatic cancers treated between 2010 and 2023. SPOREs were defined using clinically meaningful, organ-specific criteria, excluding events within 30 days of diagnosis. Death was treated as a competing event, and cumulative incidence functions were estimated with the Fine-Gray method. RESULTS: A total of 104 prostate, 59 bladder, and 195 pancreatic cancer patients (adenocarcinoma n = 178; neuroendocrine n = 17; including head and body tumors) met inclusion criteria. At 24 months, cumulative incidence of SPOREs was 3.3%, 27.2%, 40.0%, and 45.5%, respectively (p < 0.001). Overall survival differed across disease sites but did not parallel SPORE risk. SPORE incidence plateaued after 24 months for bladder and pancreatic adenocarcinoma, while prostate cancer and pancreatic neuroendocrine tumors continued to increase. Urinary obstruction predominated in prostate and bladder cancer, whereas biliary obstruction or cholangitis was most common in pancreatic cancer. Within pancreatic tumors, there was a trend toward higher SPORE incidence for head versus body tumors (48.5% vs 32.7% at 24 months, p = 0.054). CONCLUSION: SPOREs represent a substantial source of morbidity in de novo metastatic cancer. Across disease sites, risk and timing appear driven significantly by anatomic vulnerability of the primary tumor rather than metastatic virulence or prognosis. Despite differing biology, pancreatic adenocarcinoma and neuroendocrine tumors demonstrated high local morbidity. These findings suggest anatomic context may better identify patients most likely to benefit from prophylactic local therapy aimed at reducing morbidity.
引用
- Liu H, Merhav D, Tabakovic N, et al. Severe primary organ-related complications in patients with de novo metastatic cancer: implications for prophylactic local therapy. Clin Transl Radiat Oncol. 2026. PMID: 42494656. doi:10.1016/j.ctro.2026.101238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。